Adverum Biotechnologies Inc (ADVM)
5.805
+0.06
(+0.96%)
USD |
NASDAQ |
Nov 22, 10:11
Adverum Biotechnologies EPS Diluted (Quarterly): -1.30 for Sept. 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -1.30 |
June 30, 2024 | -0.89 |
March 31, 2024 | -1.50 |
December 31, 2023 | -2.32 |
September 30, 2023 | -3.26 |
June 30, 2023 | -3.13 |
March 31, 2023 | -2.90 |
December 31, 2022 | -3.30 |
September 30, 2022 | -4.00 |
June 30, 2022 | -4.40 |
March 31, 2022 | -3.80 |
December 31, 2021 | -3.50 |
September 30, 2021 | -3.90 |
June 30, 2021 | -4.50 |
March 31, 2021 | -2.90 |
December 31, 2020 | -3.90 |
September 30, 2020 | -3.10 |
June 30, 2020 | -3.60 |
March 31, 2020 | -3.10 |
December 31, 2019 | -3.00 |
September 30, 2019 | -2.50 |
June 30, 2019 | -2.30 |
March 31, 2019 | -2.30 |
December 31, 2018 | -2.40 |
Date | Value |
---|---|
September 30, 2018 | -3.40 |
June 30, 2018 | -3.00 |
March 31, 2018 | -3.00 |
December 31, 2017 | -3.20 |
September 30, 2017 | -3.20 |
June 30, 2017 | -2.70 |
March 31, 2017 | -3.80 |
December 31, 2016 | -5.40 |
September 30, 2016 | -3.50 |
June 30, 2016 | -17.60 |
March 31, 2016 | -5.70 |
December 31, 2015 | -5.450 |
September 30, 2015 | -5.50 |
June 30, 2015 | -3.80 |
March 31, 2015 | -3.80 |
December 31, 2014 | -4.567 |
September 30, 2014 | -5.00 |
June 30, 2014 | -4.007 |
March 31, 2014 | -0.8005 |
December 31, 2013 | -1.778 |
September 30, 2013 | -0.3913 |
June 30, 2013 | -0.3471 |
March 31, 2013 | -0.0236 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-4.50
Minimum
Jun 2021
-0.89
Maximum
Jun 2024
-3.115
Average
-3.195
Median
EPS Diluted (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | -0.54 |
Cassava Sciences Inc | -0.58 |
Regenxbio Inc | -1.17 |
Editas Medicine Inc | -0.75 |
Apellis Pharmaceuticals Inc | -0.46 |
EPS Diluted (Quarterly) Related Metrics
Net Income (Quarterly) | -27.13M |
Revenue (Quarterly) | 1.00M |
Total Expenses (Quarterly) | 30.22M |
Enterprise Value | -33.63M |
Profit Margin (Quarterly) | -2.71K% |
Earnings Yield | -103.5% |
Normalized Earnings Yield | -103.53 |